NYSE - Delayed Quote • USD
Bausch + Lomb Corporation (BLCO)
At close: May 17 at 4:00 PM EDT
After hours: May 17 at 7:57 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 9 |
| Avg. Estimate | 0.17 | 0.21 | 0.86 | 1.2 |
| Low Estimate | 0.14 | 0.19 | 0.82 | 1.13 |
| High Estimate | 0.25 | 0.25 | 0.94 | 1.29 |
| Year Ago EPS | 0.24 | 0.62 | 1 | 0.86 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 8 | 8 | 9 |
| Avg. Estimate | 1.59B | 1.57B | 6.34B | 6.69B |
| Low Estimate | 1.58B | 1.5B | 6.31B | 6.59B |
| High Estimate | 1.61B | 1.6B | 6.38B | 6.75B |
| Year Ago Sales | 1.4B | -- | 5.67B | 6.34B |
| Sales Growth (year/est) | 13.30% | -- | 11.80% | 5.60% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 0.18 | 0.26 | 0.24 | 0.07 |
| EPS Actual | 0.24 | 0.62 | 0.33 | 0.1 |
| Difference | 0.06 | 0.36 | 0.09 | 0.03 |
| Surprise % | 33.30% | 138.50% | 37.50% | 42.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.17 | 0.21 | 0.86 | 1.2 |
| 7 Days Ago | 0.17 | 0.21 | 0.86 | 1.2 |
| 30 Days Ago | 0.21 | 0.22 | 0.83 | 1.21 |
| 60 Days Ago | 0.2 | 0.22 | 0.82 | 1.18 |
| 90 Days Ago | 0.19 | 0.18 | 0.83 | 1.14 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 2 | 5 | 5 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | BLCO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -29.20% | -- | -- | 8.00% |
| Next Qtr. | -66.10% | -- | -- | 12.40% |
| Current Year | -14.00% | -- | -- | 5.60% |
| Next Year | 39.50% | -- | -- | 13.00% |
| Next 5 Years (per annum) | 1.50% | -- | -- | 11.14% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy | 2/2/2023 |
| Initiated | Barclays: Equal-Weight | 12/21/2022 |
| Maintains | Goldman Sachs: Neutral | 11/23/2022 |
| Maintains | JP Morgan: Neutral | 11/3/2022 |
| Maintains | RBC Capital: Outperform | 11/3/2022 |
| Maintains | Morgan Stanley: Equal-Weight | 11/3/2022 |
Related Tickers
ALC Alcon Inc.
88.83
-0.26%
NVST Envista Holdings Corporation
18.53
-3.14%
STVN Stevanato Group S.p.A.
20.71
-0.96%
COO The Cooper Companies, Inc.
97.31
-0.60%
AZTA Azenta, Inc.
50.87
-0.92%
ICUI ICU Medical, Inc.
103.99
-2.15%
BAX Baxter International Inc.
35.25
+0.23%
HAE Haemonetics Corporation
95.73
+0.98%
WST West Pharmaceutical Services, Inc.
355.64
+0.43%
ANIK Anika Therapeutics, Inc.
25.40
-0.39%